Metropolitan Life Insurance CO Gossamer Bio, Inc. Transaction History

Metropolitan Life Insurance CO

  • $281 Million
  • Q3 2024

Shares

37 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jun 14, 2023
BUY
$1.74 - $12.87 $6,876 - $50,862
3,952 New
3,952 $8.58 Million
Q4 2022

Mar 30, 2023
SELL
$1.74 - $12.87 $248 - $1,840
-143 Reduced 3.49%
3,952 $8,000
Q4 2022

Feb 15, 2023
SELL
$1.74 - $12.87 $248 - $1,840
-143 Reduced 3.49%
3,952 $8,000
Q3 2022

Jun 14, 2023
BUY
$7.21 - $14.88 $29,524 - $60,933
4,095 New
4,095 $49.1 Million
Q2 2022

Jun 20, 2023
BUY
$5.97 - $9.97 $24,447 - $40,827
4,095 New
4,095 $34,000
Q1 2022

Jun 20, 2023
BUY
$8.44 - $12.49 $34,561 - $51,146
4,095 New
4,095 $35,000
Q1 2022

Mar 30, 2023
SELL
$8.44 - $12.49 $107,196 - $158,635
-12,701 Reduced 75.62%
4,095 $35,000
Q1 2022

May 12, 2022
SELL
$8.44 - $12.49 $107,196 - $158,635
-12,701 Reduced 75.62%
4,095 $36,000
Q4 2021

Jun 21, 2023
BUY
$10.12 - $14.07 $169,975 - $236,319
16,796 New
16,796 $189,000
Q4 2021

Mar 30, 2023
BUY
$10.12 - $14.07 $8,349 - $11,607
825 Added 5.17%
16,796 $189,000
Q4 2021

Feb 15, 2022
BUY
$10.12 - $14.07 $8,349 - $11,607
825 Added 5.17%
16,796 $190,000
Q3 2021

Jun 21, 2023
BUY
$7.25 - $13.23 $115,789 - $211,296
15,971 New
15,971 $200,000
Q3 2021

Mar 30, 2023
BUY
$7.25 - $13.23 $52,968 - $96,658
7,306 Added 84.32%
15,971 $200,000
Q3 2021

Nov 15, 2021
BUY
$7.25 - $13.23 $52,968 - $96,658
7,306 Added 84.32%
15,971 $201,000
Q2 2021

Jun 21, 2023
BUY
$8.0 - $9.75 $69,320 - $84,483
8,665 New
8,665 $70,000
Q2 2021

Mar 30, 2023
SELL
$8.0 - $9.75 $53,912 - $65,705
-6,739 Reduced 43.75%
8,665 $70,000
Q2 2021

Aug 16, 2021
BUY
$8.0 - $9.75 $69,200 - $84,337
8,650 Added 57666.67%
8,665 $70,000
Q1 2021

Jun 26, 2023
BUY
$8.63 - $10.94 $132,936 - $168,519
15,404 New
15,404 $142 Million
Q1 2021

Mar 30, 2023
SELL
$8.63 - $10.94 $13,721 - $17,394
-1,590 Reduced 9.36%
15,404 $142,000
Q1 2021

May 14, 2021
SELL
$8.63 - $10.94 $146,528 - $185,750
-16,979 Reduced 99.91%
15 $142,000
Q4 2020

Jun 22, 2023
BUY
$8.3 - $13.59 $141,050 - $230,948
16,994 New
16,994 $164,000
Q3 2020

Jun 26, 2023
BUY
$11.3 - $14.75 $192,032 - $250,661
16,994 New
16,994 $210,000
Q3 2020

Mar 30, 2023
BUY
$11.3 - $14.75 $28,430 - $37,111
2,516 Added 17.38%
16,994 $210,000
Q3 2020

Nov 13, 2020
BUY
$11.3 - $14.75 $28,430 - $37,111
2,516 Added 17.38%
16,994 $211,000
Q2 2020

Jun 26, 2023
BUY
$9.52 - $15.98 $137,830 - $231,358
14,478 New
14,478 $188,000
Q2 2020

Mar 30, 2023
BUY
$9.52 - $15.98 $5,750 - $9,651
604 Added 4.35%
14,478 $188,000
Q2 2020

Aug 14, 2020
BUY
$9.52 - $15.98 $5,750 - $9,651
604 Added 4.35%
14,478 $188,000
Q1 2020

Jul 12, 2023
BUY
$8.0 - $15.48 $110,992 - $214,769
13,874 New
13,874 $140,000
Q1 2020

Mar 30, 2023
BUY
$8.0 - $15.48 $4,560 - $8,823
570 Added 4.28%
13,874 $140,000
Q1 2020

May 15, 2020
BUY
$8.0 - $15.48 $4,560 - $8,823
570 Added 4.28%
13,874 $141,000
Q4 2019

Jul 12, 2023
BUY
$14.82 - $26.79 $197,165 - $356,414
13,304 New
13,304 $207,000
Q4 2019

Mar 30, 2023
SELL
$14.82 - $26.79 $14,167 - $25,611
-956 Reduced 6.7%
13,304 $207,000
Q4 2019

Feb 14, 2020
SELL
$14.82 - $26.79 $14,167 - $25,611
-956 Reduced 6.7%
13,304 $208,000
Q3 2019

Jul 12, 2023
BUY
$16.02 - $22.47 $228,445 - $320,422
14,260 New
14,260 $239,000
Q3 2019

Mar 30, 2023
BUY
$16.02 - $22.47 $165,134 - $231,620
10,308 Added 260.83%
14,260 $239,000
Q3 2019

Nov 14, 2019
BUY
$16.02 - $22.47 $228,445 - $320,422
14,260 New
14,260 $239,000
Q2 2019

Jul 12, 2023
BUY
$16.12 - $22.89 $25,405 - $36,074
1,576 New
1,576 $35 Million

Others Institutions Holding GOSS

# of Institutions
108
Shares Held
167M
Call Options Held
430K
Put Options Held
519K
View Full List

About Gossamer Bio, Inc.

GOSS Quotes by TradingView
  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $80.8M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email